Amgen's investigational maridebart cafraglutide in a phase 1 trial led to durable weight reduction following less frequent and lower doses, the company said.
Davy James
Advertisement
Articles by Davy James
Advertisement
Latest Updated Articles
Novel Weight Loss Entrant from Amgen Challenges Duration of Effect and Dosing with Wegovy, ZepboundPublished: February 8th 2024 | Updated:
Advertisement
Advertisement
Trending on Patient Care Online
1
Investigational Oral Agent ALZ-801 Slows Brain Atrophy and Cognitive Decline in APOE4 Homozygotes with Early AD
2
Chapter 1: When to Use Epinephrine in Anaphylaxis
3
AI-Powered Diabetes Prevention Program Intervention Matches Human Coaching in Landmark Trial
4
Estetrol Phase 3 Trial Shows No Impact on Postmenopausal BP, Even in Women at High CV Risk
5
